Advertisement
News
Advertisement

Spaulding Clinical Announces Strategic Partnership with Clinigene International, India for Providing Comprehensive Early Clinical Solutions to Pharmaceutical and Biotech Clien...

Mon, 08/22/2011 - 6:41am
Bio-Medicine.Org

WEST BEND, Wis., Aug. 22, 2011 /PRNewswire/ -- Clinigene International Limited, an India-based Central and Bioanalytical Laboratory and Phase I-IV Clinical Research Organization, and Spaulding Clinical Research, LLC, US-based leading-edge Clinical Pharmacology, Cardiac Core Lab, and Medical Device Manufacturer, announce a strategic partnership agreement.  This partnership establishes a reliable, trustworthy, and cost-efficient global footprint for clinical pharmacology services providing an opportunity for both organizations to engage pharmaceutical clients strategically and accelerate First-In-Human to Proof-of-Concept clinical development.

"Pharmaceutical clients globally are increasingly seeking strategies to expedite their early clinical development, streamlining processes while maintaining high quality.  Our strategic partnership is designed to deliver this in a very cost-effective manner," states Dr. Abhijit Barve, Chief Operating Officer of Clinigene.  "The strengths of both companies are very complementary with Clinigene providing the preclinical development (through sister-company Syngene), Spaulding providing FIH/SAD/MAD, and Clinigene providing DDI and efficient Proof-of-Concept, supported by Clinigene's Central and Bioanalytical Laboratories.  With Clinigene's expertise and cost-effective approach to BA/BE and Spaulding's market-leading TQT study and Cardiac Core Lab expertise, our clients are able to easily structure a program for their compound that  delivers high-value while keeping the molecule knowledge experts involved throughout the entire early clinical development of the compound," states Randol Spaulding, CEO of Spaulding Clinical.

Clinigene operates a CAP-accredited Central Laboratory and GLP-compliant Bioanalytical Laboratory for small and large molecules, both equipped with state-of-art technology, as well as a 94-bed clinical pharmacology unit in Bangalore, India which excels at Bioavailability/Bioe

'/>"/>

SOURCE

Advertisement

Share this Story

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading